4 stories found
Apple announced record quarterly earnings, surpassing expectations despite ongoing supply chain disruptions. CEO Tim Cook highlighted strong demand for new iPhones and discussed future growth opportunities, including in India.
Lexicon Pharmaceuticals reported a GAAP EPS of -$0.04, beating estimates by $0.03, and revenue of $5.49 million, surpassing expectations by $2.35 million.
Lexicon Pharmaceuticals (LXRX) is scheduled to present data from its Phase 2b trial of Pilavapadin.
H.C. Wainwright has increased its price target for Lexicon Pharmaceuticals, Inc. (LXRX) from $4 to $6, maintaining a 'Buy' rating.